Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Mallinckrodt
QuintilesIMS
Fuji
US Army
US Department of Justice
Medtronic
Healthtrust
Harvard Business School
Deloitte

Generated: February 21, 2018

DrugPatentWatch Database Preview

PHOSLO Drug Profile

« Back to Dashboard

Which patents cover Phoslo, and what generic alternatives are available?

Phoslo is a drug marketed by Fresenius Medcl and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in PHOSLO is calcium acetate. There are two hundred and seventy-two drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the calcium acetate profile page.

US Patents and Regulatory Information for PHOSLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-001 Apr 2, 2001 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Fresenius Medcl PHOSLO GELCAPS calcium acetate CAPSULE;ORAL 021160-003 Apr 2, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-002 Apr 2, 2001 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Fresenius Medcl PHOSLO calcium acetate TABLET;ORAL 019976-001 Dec 10, 1990 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Fresenius Medcl PHOSLO GELCAPS calcium acetate CAPSULE;ORAL 021160-003 Apr 2, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PHOSLO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-001 Apr 2, 2001 ➤ Sign Up ➤ Sign Up
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-002 Apr 2, 2001 ➤ Sign Up ➤ Sign Up
Fresenius Medcl PHOSLO calcium acetate TABLET;ORAL 019976-001 Dec 10, 1990 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PHOSLO
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules EQ 169 mg calcium ➤ Subscribe 5/31/2005

Non-Orange Book US Patents for PHOSLO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,875,445 Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Colorcon
UBS
Chubb
Fuji
Federal Trade Commission
Farmers Insurance
Deloitte
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot